Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges

被引:190
作者
McKenna, DJ [1 ]
机构
[1] Univ Minnesota, Acad Hlth Ctr, Ctr Spiritual & Healing, Minneapolis, MN 55455 USA
关键词
ayahuasca; hoasca; beta-carbolines; DMT; serotonin transporters; IND; clinical studies; alcoholism; substance abuse; immune modulation;
D O I
10.1016/j.pharmathera.2004.03.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ayahuasca is a hallucinogenic beverage that is prominent in the ethnomedicine and shamanism of indigenous Amazonian tribes. Its unique pharmacology depends on the oral activity of the hallucinogen, N,N-dimethyltryptamine (DMT), which results from inhibition of monoamine oxidase (MAO) by beta-carboline alkaloids. MAO is the enzyme that normally degrades DMT in the liver and gut. Ayahuasca has long been integrated into mestizo folk medicine in the northwest Amazon. In Brazil, it is used as a sacrament by several syncretic churches. Some of these organizations have incorporated in the United States. The recreational and religious use of ayahuasca in the United States, as well as "ayahuasca tourism" in the Amazon, is increasing. The current legal status of ayahuasca or its source plants in the United States is unclear, although DMT is a Schedule I-controlled substance. One ayahuasca church has received favorable rulings in 2 federal courts in response to its petition to the Department of Justice for the right to use ayahuasca under the Religious Freedom Restoration Act. A biomedical study of one of the churches, the Uniao do Vegetal (UDV), indicated that ayahuasca may have therapeutic applications for the treatment of alcoholism, substance abuse, and possibly other disorders. Clinical studies conducted in Spain have demonstrated that ayahuasca can be used safely in normal healthy adults, but have done little to clarify its potential therapeutic uses. Because of ayahuasca's ill-defined legal status and variable botanical and chemical composition, clinical investigations in the United States, ideally under an approved Investigational New Drug (IND) protocol, are complicated by both regulatory and methodological issues. This article provides an overview of ayahuasca and discusses some of the challenges that must be overcome before it can be clinically investigated in the United States. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:111 / 129
页数:19
相关论文
共 110 条
[1]  
AIRAKSINEN MM, 1981, MED BIOL, V59, P21
[2]   THE SIMPLE BETA-CARBOLINE ALKALOIDS [J].
ALLEN, JRF ;
HOLMSTEDT, BR .
PHYTOCHEMISTRY, 1980, 19 (08) :1573-1582
[3]  
[Anonymous], YB CROSS CULTURAL ME
[4]  
[Anonymous], 1975, WIZARD UPPER AMAZON
[5]  
[Anonymous], 1998, MAPS
[6]  
Barker S A, 1981, Int Rev Neurobiol, V22, P83, DOI 10.1016/S0074-7742(08)60291-3
[7]   METABOLISM OF THE HALLUCINOGEN N,N-DIMETHYLTRYPTAMINE IN RAT-BRAIN HOMOGENATES [J].
BARKER, SA ;
MONTI, JA ;
CHRISTIAN, ST .
BIOCHEMICAL PHARMACOLOGY, 1980, 29 (07) :1049-1057
[8]   Biogenic amine transporters: regulation in flux [J].
Blakely, RD ;
Bauman, AL .
CURRENT OPINION IN NEUROBIOLOGY, 2000, 10 (03) :328-336
[9]  
BLOOM F, 1982, BETA CARBOLINES TETR
[10]   MONOAMINE-OXIDASE INHIBITION IN BRAIN AND LIVER PRODUCED BY BETA-CARBOLINES - STRUCTURE-ACTIVITY-RELATIONSHIPS AND SUBSTRATE-SPECIFICITY [J].
BUCKHOLTZ, NS ;
BOGGAN, WO .
BIOCHEMICAL PHARMACOLOGY, 1977, 26 (21) :1991-1996